Rising Biosciences Inc (RBII)

[StockRocket]

Lets review RSII MODEL: compounding labs/pharmacies/physicians/chemists involved:

PRODUCT TO MARKET VERY FAST FILLING RX'S WITH THE HIGHEST QUALITY MEDICAL GRADE CANNABIS FORMS THAT ARE ACCURATE....GOING TO LEAD THE WAY THEY SAID ONE OF THE NEW DIRECTORS FROM THE NEWLY FORMED RISING BIOSCIENCES TEAM...No one else is in the industry is doing it with the certified accuracy and brand that we will be doing it. Will be branding and marketing to med cannabis legal states and NWAV clinics which will be an instant customer base for them...brilliant move by the CEO Robert Weber.

NO FDA involvement that takes years and millions of dollars and only a 10% chance of getting a approval for an indication. ..

1- What is “compounding”?
In general, compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.

2-Why do some patients need compounded drugs?
Sometimes, the health needs of a patient cannot be met by an FDA-approved medication. For example: if a patient has an allergy and needs a medication to be made without a certain dye; or
if an elderly patient or a child can’t swallow a pill and needs a medicine in a liquid form that is not otherwise available.

3-Are compounded drugs approved by the FDA?
Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.
Generally, state boards of pharmacy will continue to have primary responsibility for the day-to-day oversight of state-licensed pharmacies that compound drugs in accordance with the conditions of section 503A of the FDCA, although FDA retains some authority over their operations. However, outsourcing facilities that register under section 503B are regulated by FDA and must comply with CGMP requirements and will be inspected by FDA according to a risk-based schedule.

NOW...OWCP is a pharmaceutical co....that route is so much riskier and cost millions and millions of dollars to do studies and submit to FDA for approval....MOST get denied or fail phase 1 and 2 studies....RSII model has a different set of regulations that are PERFECT for the medical cannabis industry....Revs are instant and their are no FDA guidleines...This is going to be huge...very huge.